Toboroz
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
NCT07665437· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07441642· 2. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
NCT07431177· 2. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
NCT06858319· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis
NCT07029555· 1. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
NCT06947993· 2. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06840392· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
NCT06797518· 2. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
NCT06597019· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06655896· 2. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
NCT06649110· 1/2. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06470048· 2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
NCT06581198· 2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941· 2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
NCT06517758· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05939414· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Toboroz
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
NCT05948943· 2/3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
NCT05985915· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
NCT05885555· 2. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
NCT05562466· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
NCT05624749· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
NCT05653349· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
NCT05653219· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
NCT05456191· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Asciminib Roll-over Study
NCT04877522· 4. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
NCT05349214· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
NCT05360446· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
NCT05147220· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
NCT04940052· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
NCT04926818· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
NCT04557462· 3. fázis· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Fut, nem toboroz
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
NCT04417621· 2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829· 4. fázis· Novartis Pharmaceuticals· Forrás